<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141411">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02121483</url>
  </required_header>
  <id_info>
    <org_study_id>1245.87</org_study_id>
    <secondary_id>2013-002304-14</secondary_id>
    <nct_id>NCT02121483</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus</brief_title>
  <official_title>An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the
      safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18
      years with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC0-infinity (Area under the plasma concentration-time curve from time zero to infinite time)</measure>
    <time_frame>up to Day 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (Area under the plasma concentration-time curve from time zero to the the time of the last quantifiable concentration)</measure>
    <time_frame>up to Day 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum observed plasma concentration)</measure>
    <time_frame>up to Day 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax (Time of maximum observed plasma concentration)</measure>
    <time_frame>up to Day 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (Terminal half-life in plasma)</measure>
    <time_frame>up to Day 3</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urinary glucose excretion</measure>
    <time_frame>over 24 hours after study drug intake</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose (mg/dL)</measure>
    <time_frame>24 hours after study drug intake</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 8-point plasma glucose profile</measure>
    <time_frame>over 24 hours after study drug intake</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>empagliflozin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive a high dose of empagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive a medium dose of empagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive a low dose of empagliflozin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin medium dose</intervention_name>
    <arm_group_label>empagliflozin medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin high dose</intervention_name>
    <arm_group_label>empagliflozin high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin low dose</intervention_name>
    <arm_group_label>empagliflozin low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Children and adolescents with type 2 diabetes mellitus

          -  Insufficient glycaemic control (6.5% &lt; HbA1c &gt; 10.5%) despite diet and exercise
             and/or metformin

          -  Negative for Islet Cell Antigen and Glutamic Acid Decarboxylase autoantibodies and
             fasting C-peptide levels &gt;= 0.85 ng/ml

          -  BMI &gt; 50th percentile for age and sex

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level &gt; 240 mg/dl (&gt; 13.3 mmol/l)

          -  History of acute metabolic decompensation such as diabetic ketoacidosis within 3
             months before screening

          -  Current insulin therapy or having received insulin within 4 weeks before
             randomisation

          -  Treatment with weight reduction medications within 4 weeks before randomisation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1245.87.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1245.87.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1245.87.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
